Product nameAnti-FGF9 / GAF antibody
See all FGF9 / GAF primary antibodies
DescriptionRabbit polyclonal to FGF9 / GAF
Tested applicationsSuitable for: IHC-P, WB, ELISA, Neutralisingmore details
Species reactivityReacts with: Mouse, Rat
Recombinant fragment corresponding to FGF9/ GAF.
- Recombinant rat FGF9 / GAF protein (ab9745) can be used as a positive control in WB.
Previously labelled as FGF9.
FormLyophilised:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPBS, pH 7.4, no preservative, sterile filtered
Concentration information loading...
PurityImmunogen affinity purified
Light chain typeunknown
Our Abpromise guarantee covers the use of ab9743 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent dilution. PubMed: 17192470|
|WB||Use a concentration of 0.1 - 0.2 µg/ml.|
|ELISA||Use a concentration of 0.5 µg/ml. Allows the detection of 0.2 - 0.4 ng/well of recombinant mFGF-9 (using 100µl/well antibody solution).|
|Neutralising||Use a concentration of 0.025 - 0.06 µg/ml. for one-half maximal inhibition [ND50] of the biological activity of mFGF-9 (1.5 ng/ml).|
FunctionMay have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
Tissue specificityGlial cells.
Involvement in diseaseDefects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
Sequence similaritiesBelongs to the heparin-binding growth factors family.
modificationsThree molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
- Information by UniProt
- FGF 9 antibody
- FGF-9 antibody
- FGF9 antibody
All lanes : Anti-FGF9 / GAF antibody (ab9743) at 1/500 dilution
Lane 1 : Recombinant FGF9 / GAF
Lane 2 : Rat cerebral cortex membrane whole tissue lysate. at 15 µg
All lanes : Mouse anti-rabbit IgG monoclonal at 1/1000 dilution
Developed using the ECL technique.
Exposure time: 30 seconds
Blocking Step: 1% Milk for 1 hour at 16°C
Gel Running Conditons: 15% gel Reduced, denaturing
Observed Bands: 23kDa recombinant FGF9 - 46kDa in cerebral cortex membrane fraction.
ab9743 staining FGF9 / GAF in mouse lymph node tissue by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded tissue sections). The sections were fixed in paraformaldehye prior to blocking with 10% serum for 1 hour at 20°C. The primary antibody was diluted 1/100 and incubated with the sample for 12 hours at 4°C. An HRP-conjugated Goat anti-Rabbit polyclonal was used as the secondary antibody, diluted 1/200.
This product has been referenced in:
- Dong N et al. MicroRNA-182 prevents vascular smooth muscle cell dedifferentiation via FGF9/PDGFRß signaling. Int J Mol Med 39:791-798 (2017). WB . Read more (PubMed: 28259995) »
- Steffes G et al. Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) are two new mutations of Lmx1a causing severe cochlear and vestibular defects. PLoS One 7:e51065 (2012). IHC . Read more (PubMed: 23226461) »